ASBMR

Mediterranean Diet Seems to Lower Fall Risk

September 21, 2020

Adherence to a Mediterranean diet is associated with improved musculoskeletal health and fewer falls, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting held earlier this month.

Oral Glucocorticoids and Fracture Risk in RA

September 21, 2020

Low-dose oral glucocorticoid therapy increases only vertebral fracture risk in rheumatoid arthritis patients, a study shows.

Low Osteocalcin Linked to Glucocorticoid-Induced Diabetes

September 16, 2020

Low levels of osteocalcin are associated with an increased risk of diabetes in patients treated with glucocorticoids, according to a study presented on Sept. 11 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which wrapped this week as a virtual meeting.

Low Vitamin D May Worsen COVID-19

September 16, 2020

Improving vitamin D status might decrease the risk of developing severe respiratory distress and death in COVID-19 cases, shows an observational study presented September 11 at the American Society for Bone and Mineral Research (ASBMR) which was held virtually this week.

Bisphosphonate Use Associated with Increased Fracture Risk

September 16, 2020

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

Teriparatide for Bone Formation in Hip Fractures

September 16, 2020

Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.

Zoledronate As Booster Drug in Fight Against Osteoporosis

September 14, 2020

Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.

Q&A: Vitamin D and Bone Mineral Density

September 14, 2020

High-dose vitamin D supplementation compared with standard-dose vitamin D supplementation resulted in a greater loss of volumetric bone mineral density in women but not men, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

Q&A: Anabolic Agents for Osteoporosis

September 14, 2020

Three months of treatment with the osteoporosis drug abaloparatide (Tymlos, Radius) has a robust effect on bone formation in postmenopausal women with osteoporosis, according to a study presented on Sept. 12 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

Abaloparatide Shown to Increase Bone Mineral Density

September 11, 2020

The osteoporosis treatment abaloparatide has been shown to increase bone mineral density of the lumbar spine, total hip and femoral neck bone in patients with osteoporosis who are at high risk for fracture, according to a study presented today at the American Society for Bone and Mineral Research annual meeting which is being held virtually through Tuesday.